Journal ArticleDOI
Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial
Reads0
Chats0
TLDR
Locally injected eASCs appear to be a simple, safe, and beneficial therapy for perianal fistula in Crohn’s disease patients, and additional studies are needed to further confirm the efficacy of the eASC.Abstract:
Purpose
The management of perianal fistula in patients with Crohn’s disease is an extremely challenging medical problem as many fistulas do not respond to available treatments The objectives were to assess the safety and efficacy of a suspension of expanded adipose-derived allogeneic mesenchymal stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s diseaseread more
Citations
More filters
Journal ArticleDOI
Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases
Saad Jasim,Alexei Valerievich Yumashev,Walid Kamal Abdelbasset,Ria Margiana,Alexander V. Markov,Wanich Suksatan,Benjamin Pineda,Lakshmi Thangavelu,Seyed Hossein Ahmadi +8 more
TL;DR: In this article , the authors present the last observations of researches on different mesenchymal stem cells and their efficiency and feasibility in the clinical treatment of several autoimmune disorders including rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, autoimmune liver disease, and Sjogren's syndrome.
Journal ArticleDOI
Mesenchymal Stromal Cell Therapy for Crohn's Disease
TL;DR: The potential therapeutic role of MSC therapy for CD, which is predominantly related to its immunomodulatory role, is discussed and the characteristics of M SCs derived from patients with CD and its pharmacological interaction are outlined.
Human Adipose Stromal Cells Increase Survival and Mesenteric Perfusion Following Intestinal Ischemia and Reperfusion Injury
Amanda R. Jensen,Dominique L. Doster,Dominique L. Doster,E. Bailey Hunsberger,E. Bailey Hunsberger,Morenci M. Manning,Morenci M. Manning,Samantha M. Stokes,Samantha M. Stokes,Daria Barwinska,Keith L. March,Mervin C. Yoder,Troy A. Markel +12 more
TL;DR: In this article, the authors hypothesized that human adipose-derived stromal cells (hASCs) would increase survival and mesenteric perfusion to a colorectal mesh.
Journal ArticleDOI
Is Stem Cell Therapy Ready for Prime Time in Treatment of Inflammatory Bowel Diseases
TL;DR: Recent trials have produced promising results for HSCT and mesenchymal stromal cell therapy as alternatives to systemic therapies and antibiotics for patients with inflammatory bowel diseases, but are these immunotherapies ready for prime time?
Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled Trial
Hôpital Pontchaillou,Hôpital Saint-Louis,Chu Nantes,Chu Sart Tilman,Hôpital Nord,GH Diaconesses-Croix Saint +5 more
TL;DR: A multicentre, open-label, randomised controlled trial comparing seton removal alone with AFP insertion in 106 Crohn’s disease patients with non- or mildly active disease having at least one ano-perineal fistula tract drained for more than 1 month found no interaction in treatment effect with complexity stratum.
References
More filters
Journal ArticleDOI
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
Massimo Di Nicola,Carmelo Carlo-Stella,Michele Magni,Marco Milanesi,Paolo Longoni,Paola Matteucci,Salvatore Grisanti,Alessandro M. Gianni +7 more
TL;DR: The data demonstrate that autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Human mesenchymal stem cells modulate B-cell functions
Anna Corcione,Federica Benvenuto,Elisa Ferretti,Debora Giunti,Valentina Cappiello,Francesco Cazzanti,Marco Risso,Francesca Gualandi,Giovanni Luigi Mancardi,Vito Pistoia,Antonio Uccelli +10 more
TL;DR: The results further support the potential therapeutic use of hMSCs in immune-mediated disorders, including those in which B cells play a major role.
Journal ArticleDOI
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
TL;DR: Undifferentiated and differentiated MSC do not elicit alloreactive lymphocyte proliferative responses and modulate immune responses, and the findings support that MSC can be transplantable between HLA-incompatible individuals.
Journal ArticleDOI
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
Mauro Krampera,Sarah Glennie,Julian Dyson,Diane Scott,R. Laylor,Elizabeth Simpson,Francesco Dazzi +6 more
TL;DR: It is suggested that MSCs physically hinder T cells from the contact with APCs in a noncognate fashion and inhibit naive and memory T-cell responses to their cognate antigens.